Simulations Plus Inc

Simulations Plus Inc has a market capitalization of $270.35 million and a price-to-book ratio of 2.17, indicating a premium valuation relative to its book value. The company holds $30.85 million in cash and equivalents, with no long-term debt, and a current ratio of 7.67, suggesting strong short-term liquidity. The company's profitability metrics are negative, with a return on equity of -51.86% and a return on assets of -49.05%. These figures are below the industry median for healthcare technology firms, indicating underperformance in generating returns from equity and asset base. Geographically, Simulations Plus Inc derives the majority of its revenue from North America, with a concentration risk score of high due to over 80% of revenue coming from this region. The company operates in a single business segment focused on simulation software and services for drug development. The company's revenue growth is expected to remain flat in the current fiscal year, with a slight decline projected for the next fiscal year. This outlook is supported by a historical revenue of $79.18 million and a negative operating income of $70.09 million, indicating challenges in scaling operations profitably. The risk assessment for Simulations Plus Inc indicates low liquidity and dilution risks, with no immediate filing-based flags detected. However, the company's negative net income of $64.72 million and free cash flow of -$60.34 million suggest potential future dilution pressures if capital needs increase. Recent events include analyst price targets ranging from $16.00 to $31.00, with a mean of $24.00 and a median of $24.50. The mean recommendation is 2.29, indicating a generally positive outlook from analysts, with two strong buy ratings and one buy rating.